OUR TECHNOLOGY

BioSavita's proprietary S. cerevisiaestrains were engineered for modified N-glycosylation with only core endoplasmic reticulum (ER) glycan as conserved in all eukaryotes. 

There is no hyper-mannosylation in products from these yeast strains.

Yeast have several advantages when compared with current processes used for vaccine production, including (i) FDA approved process for large scale vaccine production (ii) Rapidly and scalable shorter production cycle (that may provide a new vaccines for the Covid-19 pandemic threat) (iii) available microbial fermentation facilities with low operating costs throughout the world (iv) neither viral nor endotoxin contamination thereby reducing purification and quality control costs. 

BioSavita uses synthetic biological approaches and provides a platform for construction of “yeast factories” for the accelerated and cost-effective production of recombinant antibodies, proteins and VLP vaccines. Using our yeast platform, we have produced complex multimeric proteins such as hemoglobin, antibodies, antibody-fusion proteins, Ebola Z-Mapp antibodies and Ebola VLPs.